Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Takuya Tada[1*], Hao Zhou[1*], Marie I. Samanovic[2,3*], Belinda M. Dcosta[1], Amber Cornelius[2,3], Mark J. Mulligan[1,2,3+] and Nathaniel R. Landau[1+**]

Affiliation:

[1]Department of Microbiology, NYU Grossman School of Medicine, New York, NY, USA.

[2]Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.

[3]NYU Langone Vaccine Center, NYU Grossman School of Medicine, New York, NY, USA.

*Contributed equally to this study

+Contributed equally to this study

**Corresponding author:

Nathaniel R. Landau, Ph.D.

NYU Grossman School of Medicine

430 East 29th Street, Alexandria West Building, Rm 509, New York, NY 10016

Email: nathaniel.landau@med.nyu.edu

Phone: (212) 263-9197

Summary

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC_{50} <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines from two vaccine platforms have been granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization: mRNA-based (Pfizer and Moderna) and adenoviral vector-based (Johnson & Johnson (J&J)), all of which have been shown to be highly effective. The mRNA-based vaccines were 94-95% effective in preventing COVID-19[1] whereas the adenoviral vector-based J&J vaccine had 66.9% efficacy in preventing moderate to severe disease[2]. However, the ongoing emergence of highly transmissible variants with mutations in the spike protein raises concerns regarding possible decreases in vaccine effectiveness due to spike protein antigenic variability.

SARS-CoV-2 variants have been classified by the World Health Organization (WHO) based on increased transmissibility and/or pathogenicity as variants of concern (VOC; Alpha (B.1.1.7), Beta (B.1.351), Gamma (B.1.1.248) and Delta (B.1.617.2) and variants of interest (VOI; Epsilon (B.1.427/B.1.429), Iota (B.1.526), and Delta plus (AY.1) and Lambda (C.37)[3]. The increased transmissibility and/or pathogenicity of the variants is due, at least in part, to mutations in the spike protein RBD that increase its affinity for ACE2 on target cells. Mutations in the Beta, Gamma and Delta variant spike RBDs have been shown to cause partial resistance to neutralization by the serum antibodies of vaccinated and convalescent individuals and therapeutic monoclonal antibodies[4-11].

This study compared the neutralization titers of serum antibodies from individuals immunized with three U.S. FDA Emergency use authorization vaccines (BNT162b2,

56 mRNA-1273 and Ad26.COV2.S) against viruses with the VOC and Lambda spike proteins.
57 The study groups were controlled for age, clinical co-morbidity, history of pre-vaccination
58 infection and sera were collected on similar days post-vaccination. The results
59 demonstrate a high level of cross-neutralization by antibodies elicited by BNT162b2 and
60 mRNA-1273 on the variants but significantly decreased neutralization by those elicited by
61 the single dose Ad26.COV2.S.
62

Methods

Clinical Samples

Convalescent sera were collected 32-57 days post-symptom onset. For the early time-point, BNT162b2 and Moderna-vaccinated sera were collected on day 28 and 35, respectively, 7 days post-second immunization. For the later time-point, BNT162b2-vaccinated sera were on average collected 90 days post-second immunization and mRNA-1273-vaccinated sera were collected on average 80 days post-second immunization. Ad26.COV2.S-vaccinated sera were collected, on average, 82 days post-immunization **(Table S2)**. Blood was drawn at the NYU Vaccine Center with written consent under IRB approved protocols (IRB 18-02035 and IRB 18-02037)**.** REGN10933 and REGN10987 were generated as previously described[12].

SARS-CoV-2 spike lentiviral pseudotypes

Lentiviruses pseudotyped by variant SARS-CoV-2 spikes were produced as previously reported[13] and normalized for reverse transcriptase (RT) activity. Neutralization titers of sera, monoclonal antibody and soluble ACE2 (sACE2)[14] were determined as previously described[13].

sACE2 pull-down assay

sACE2-bound-beads were mixed with pseudotyped virions as previously described[14]. The amount of virus bound was quantified by immunoblot analysis of bound p24.

Statistical Analysis

86 All experiments were in technical duplicates or triplicates. Statistical significance was
87 determined by two-tailed, unpaired t-test with confidence intervals shown as the mean ±
88 SD or SEM. (*P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001). Spike protein structure
89 (7BNM)[15] was downloaded from the Protein Data Bank.
90

91 **Results**

92 **Variant pseudotyped lentiviruses.** The Delta plus spike contains K417N, L452R and
93 T478K in the RBD **(Figure S1A)**. The Lambda spike protein contains novel L452Q and
94 F490S mutations in the RBD **(Figure S1A)**. We previously described the production of
95 lentiviruses pseudotyped by the Alpha, Beta, Gamma and Delta spike proteins and here
96 report the generation of pseudotypes with the Delta plus and Lambda variant spike
97 proteins and the individual constituent mutations. The variant spike proteins were well
98 expressed, proteolytically processed and incorporated into lentiviral virions at a level
99 similar to that of the parental D614G spike protein in the producer cells and virions **(Figure**
100 **S1B)**. The measurement of neutralizing antibody titers with such pseudotypes has been
101 shown to yield results consistent with those obtained with the live virus plaque reduction
102 neutralization test[16].

103

104 **Reduced sensitivity of virus with variant spikes to neutralization by convalescent**
105 **sera and mRNA vaccine-elicited antibodies.** Sera from individuals who had been
106 infected prior to the emergence of the variants (collected 32-57 days post symptom onset)
107 neutralized virus with the D614G spike protein with an average IC_{50} titer of 346 and
108 neutralized the Alpha variant with a similar titer (IC_{50} of 305). Neutralizing titers for Beta,
109 Delta, Delta plus and Lambda variants were decreased 3.2-4.9-fold relative to D614G,
110 indicative of a modest resistance to neutralization **(Figure 1A, Table S1)**. The sera of
111 individuals vaccinated with BNT162b2 and mRNA-1273 that were collected 7-days post-
112 second injection – a peak antibody response timepoint - neutralized virus with the D614G
113 spike with significantly higher titer (1835 and 1594, respectively) relative to the

114 convalescent sera, and the antibodies cross-reacted on the variants with a modest 2.5-
115 4.0-fold decrease in titer **(Figure 1A)**. The resistance of the Beta variant was attributed
116 to the E484K mutation whereas resistance of the Delta variant was attributed to the L452R
117 mutation **(Figure S2)**. The resistance of the lambda variant was attributed to both the
118 L452Q and F490S mutations **(Figure S2).**
119
120 **Resistance of viruses with variant spike proteins to neutralization by Ad26.COV2.S-**
121 **elicited antibodies**. We next compared the neutralizing titers of antibodies elicited by the
122 BNT162b2 and mRNA-1273 mRNA vaccines with that of the Ad26.COV2.S adenoviral
123 vector-based vaccine. The sera analyzed were collected from individuals at similar time-
124 points post-final injection, on average (90 days for BNT162b2, 80 days for mRNA-1273
125 and 82 days for Ad26.COV2.S; **Table S2**) and from individuals of similar age and with
126 similar clinical co-morbidities **(Table S2)**. None of the participants had a history of COVID-
127 19 pre- or post-vaccination and all were negative for antibodies against the SARS-CoV-
128 2 N protein **(Table S2)**. The results showed that BNT162b2 sera neutralized virus with
129 the D614G and Alpha spikes with an average titer of 695 and 626. Compared to the
130 D614G, the neutralizing titer against Beta was decreased 6.1-fold and Delta plus was
131 decreased 2.7-fold. Results for the mRNA-1273 vaccine were similar with a 3.3-fold
132 decrease in neutralizing titer for Delta plus and 4.6-fold for Beta. Ad26.COV2.S sera
133 neutralized D614G and Alpha variants with average IC_{50} titers of 221 and 232,
134 respectively, and neutralized the variants with titers that were decreased by 5.4-fold for
135 Delta plus to 6.7-fold for the Beta variant as compared to D614G **(Figure 1B).**

136 Presentation of the data grouped by variant shows the decreased neutralizing titers
137 against the variants by sera of the Ad26.COV2.S-vaccinated individuals **(Figure 1C)**.
138
139 **The L452R/Q mutation of the Delta plus and Lambda spike proteins increases**
140 **infectivity and affinity for ACE2.** Measurement of the infectivity of the pseudotyped
141 viruses, normalized for particle number, showed that the Lambda variant spike protein
142 increased viral infectivity by 2-fold **(Figure 2A)**, an increase equivalent to that of the Delta
143 and Delta plus variants. The increase was due to the L452Q mutation and was similar to
144 that of the L452R found in the Delta and Delta plus variants. The other mutations (Δ246-
145 252, G75V-T76I, F490S and T859N) had no significant effect on infectivity **(Figure 2A)**.
146 Measurement of the relative affinity of the variant spike proteins for ACE2 using sACE2
147 neutralization assay showed that variant spikes had a 3-fold increase in sACE2 binding
148 **(Figure 2B)**. This increase was confirmed in a virion:ACE2 binding assay **(Figure 2C)**.
149 The increase was caused by the L452R and L452Q mutation and were similar to the
150 increase caused by the N501Y mutation[17,18].
151
152 **Neutralization by REGN10933 and REGN10987.** Analysis of REGN10933 and
153 REGN10987 monoclonal antibodies that constitute the REGN-COV2 therapy showed that
154 REGN10933 had decreased activity against the Beta variant spike which resulted in a
155 127-fold decrease in neutralizing titer. REGN10933 also had decreased activity against
156 the Delta plus variant which resulted in a 92.7-fold decrease in neutralizing titer. The
157 resistance to REGN10933 was attributed to K417N and E484K **(Figure S3)**. REGN10933
158 neutralized virus with the Delta variant spike with a 12-fold decrease in titer which had

159 only a minor effect on the activity of the cocktail. REGN10987 showed a minor reduction
160 in neutralizing titer of virus with the Beta, Delta, Delta plus and Lambda variant spikes but
161 this had little effect on neutralization of the virus by the cocktail **(Figure 2D).** The
162 resistance of variants to REGN10987 was attributed to the L452R/Q **(Figure S3)**.
163

164 ## Discussion

165 Several reports have shown partial resistance of SARS-CoV-2 VOCs to vaccine-elicited
166 antibodies[4-11]. The data shown here extend those findings to the Delta plus and Lambda
167 variants. Delta plus and Lambda, VOIs, both displayed a degree of resistance to mRNA
168 vaccine-elicited antibodies similar to that of the Beta and Delta variants. In sera collected
169 ~3 months post-second immunization, BNT162b2 and mRNA-1273 mRNA vaccine-
170 elicited antibodies neutralized the variants with a modest 3-fold average decrease in titer
171 resulting in an average IC_{50} of about 1:600, a titer that is greater than that of convalescent
172 sera and likely, in combination with post-vaccination T- and B-cell memory responses, to
173 provide durable protection. Ad26.COV2.S vaccination-elicited neutralizing antibodies
174 showed a more pronounced decrease in neutralizing titer against the variants, raising the
175 potential for decreased protection against the VOCs and the Lambda variant. Vaccination
176 with Ad26.COV2.S resulted in IC_{50} titers against Beta, Delta, Delta plus and Lambda
177 variants that decreased 5-7-fold, resulting in mean neutralizing antibody titers of 33, 30,
178 41, and 36 against viruses with the Beta, Delta, Delta plus and Lambda variant spikes,
179 respectively, which according to mathematical modeling, could result in decreased
180 protection against infection[19]. Modeling predicts that 50% protection from infection is
181 provided by a titer that is 20% that of the mean convalescent titer. In this study, given a
182 mean convalescent titer of 346 **(Table S1)**, 50% protection would correspond to an IC_{50}
183 of 69. The titer required to protect against severe disease was shown to be 3% that of the
184 mean titer of convalescent sera which in this study corresponds to a titer of 10. In a
185 published report of phase 3 trial data, a single dose of Ad26.COV2.S, 28 days post
186 administration, provided 64.0% protection against moderate to severe disease and 81.7%

187 against severe-critical COVID-19 in a country where 95% of circulating SARS-CoV-2 was
188 the Beta variant[2]. The authors considered possible roles for non-neutralizing antibody Fc-
189 mediated effector functions and the role of the T cell response in maintaining protection
190 against the partially neutralizing antibody-resistant Beta variant.
191
192 The data reported here differ somewhat from those reported by Jongeneelen *et al*. who
193 found that Ad26.COV2.S-elicited antibody titers were mostly maintained against the
194 variants[20]. In addition, Alter *et al*. reported a 5-fold decrease in neutralizing antibody titer
195 against Beta and 3.3-fold decrease against the Gamma variant by the sera from
196 Ad26.COV2.S vaccination[21] which were less pronounced than those reported here. While
197 the studies used similar assays to measure antibody neutralization and analyzed sera
198 collected at a similar time-point post-immunization, it is possible that differences in the
199 study populations accounted for the experimental differences.
200
201 Several recent studies have shown that boosting a single immunization of the
202 ChAdOx1nCoV-19 adenoviral vector vaccine with BNT162b2 resulted in high neutralizing
203 titer against the VOCs[22-24]. It is likely that neutralizing antibody titers against the VOCs
204 elicited by the single shot Ad26.COV2.S could similarly be improved by boosting with a
205 second immunization or by a heterologous boost with one of the mRNA vaccines. While
206 a single dose vaccination has advantages, the benefit provided by a second immunization
207 may be well worth the inconvenience.
208

209 The data presented here emphasize the importance of surveillance for breakthrough
210 infections with the increased prevalence of highly transmissible variants. If an increase in
211 breakthrough infections accompanied by severe COVID-19 is found following adenovirus
212 vector or mRNA vaccination, this would provide a rationale for public health policy-makers
213 and manufacturers to consider booster immunizations that would increase protection
214 against the VOCs and Lambda variant. As such a need is not currently evident, the public
215 health apparatus should focus on primary immunization in the U.S. and globally.

216 **Figure legends**

217

218 **Figure 1. Comparison of neutralization titers of variant spike protein pseudotyped**
219 **viruses by convalescent sera, antibodies elicited by BNT162b2, mRNA-1273,**
220 **Ad26.COV2.S.**

221 (A) Neutralization of variant spike protein pseudotyped viruses by convalescent serum
222 (n=8) (left). Neutralizing titers of serum samples from BNT162b2 vaccinated individuals
223 (n=15) (middle). Neutralizing titers of serum samples from mRNA-1273 vaccinated
224 donors (n=6) (right). The serum was collected at early time point (7 days after second
225 immunization). The neutralization IC_{50} from individual donors is shown. Significance is
226 based on two-sided t-test.

227 (B) Comparison of neutralization of variants by convalescent serum (n=8, the same
228 donors in A), BNT162b2 vaccinated individuals (n=9), mRNA-1273 vaccinated donors
229 (n=8), Ad26.COV2.S vaccinated donors (n=10), sera from vaccinated individuals were
230 collected at later time points (90, 80, 82 days on average after last immunization of each
231 vaccine, see the table S2) . Each line shows individual donors.

232 (C) Comparison of neutralization potency of each vaccine by different SARS-CoV-2
233 variants. The neutralization IC_{50} from individual donors vaccinated by BNT162b2 (yellow),
234 mRNA-1273 (pink), Ad26.COV2.S (black) is shown. Significance is based on two-sided
235 t-test.

236

237 **Figure 2. Neutralization of variant spike protein pseudotyped viruses by**
238 **monoclonal antibodies and sACE2.**

239 (A) Infectivity of virus pseudotyped by variant and D614G spike proteins. Viruses were
240 normalized for RT activity and applied to target cells. Infectivity of viruses pseudotyped
241 with the variant proteins or the individual Lambda mutations were tested on ACE2.293T.
242 Luciferase activity was measured two days post-infection. Significance was based on two-
243 sided t-test.
244 (B) Neutralization of variant spike protein variants by sACE2. Viruses pseudotyped with
245 variant spike proteins were incubated with a serially diluted recombinant sACE2 and then
246 applied to ACE2.293T cells. Each plot represents the percent infectivity of D614G and
247 other mutated spike pseudotyped virus. The diagram shows the IC_{50} for each curve.
248 (C) Nickel beads were coated for 1 hour with 1, 0.5 and 0.1 μg of sACE2 proteins.
249 Unbound protein was removed and SARS-CoV-2 variant pseudotyped virions (D614G,
250 Delta, Lambda) were incubated with the beads. After 1 hour, the bound virions were
251 analyzed on an immunoblot with antibody p24 antibody. Beads-bound p24 (ng) was
252 calculated and indicated in the bottom (left). Input virions were analyzed on an
253 immunoblot with anti-p24 antibody (middle). Input sACE2 proteins were analyzed on an
254 immunoblot with anti-His-tag antibody (right).
255 (D) Neutralization of Beta, Delta, Delta plus and Lambda variant spike protein variants by
256 REGN10933 and REGN10987 monoclonal antibodies. Neutralization of D614G and
257 variant pseudotyped viruses by REGN10933 (left), REGN10987 (middle), and 1:1 ratio of
258 REGN10933 and REGN10987 (right). The IC_{50} values of REGN10933, REGN10987 and
259 the cocktail is shown in the table.
260
261

262 **Supplemental Figure S1.**

263 **The structure of variant spikes and immunoblot analysis of spike proteins.**

264 (A) The domain structure of the SARS-CoV-2 spike is diagrammed with Delta (B.1.617.2),
265 Delta plus (AY.1), Lambda (C.37) variant amino acid residues indicated. NTD, N-terminal
266 domain; RBD, receptor-binding domain; RBM, receptor-binding motif; SD1 subdomain 1;
267 SD2, subdomain 2; CS, cleavage site; FP, fusion peptide; HR1, heptad repeat 1; HR2,
268 heptad repeat 2; TM, transmembrane region; IC, intracellular domain. Key mutations are
269 shown in 3D structure (top view).

270 (B) Immunoblot analysis of the Delta (B.1.617.2), Delta plus (AY.1), single point mutated
271 of Lambda (C.37) variant, Lambda (C.37) variant spike proteins in transfected 293T cells.
272 Pseudotyped viruses were produced by transfection of 293T cells. Two days post-
273 transfection, virions were analyzed on an immunoblot probed with anti-spike antibody and
274 anti-HIV-1 p24. The cell lysates were probed with anti-spike antibody and anti-GAPDH
275 antibodies as a loading control.

276

277 **Supplemental Figure S2.**

278 **Neutralization titers of spike protein pseudotyped viruses (single point mutations)**
279 **by convalescent sera, antibodies elicited by BNT162b2, mRNA-1273.**

280 (A) Neutralization of variant spike protein (single point mutations) pseudotyped viruses by
281 convalescent serum (n=8). Dots represent the IC_{50} of single donors.

282 (B) Neutralizing titers of serum samples from BNT162b2 vaccinated individuals (n=15).
283 The serum was collected at early time point (7 days after second immunization). Each dot
284 represents the IC_{50} for a single donor.

285 (C) Neutralizing titers of serum samples from mRNA-1273 vaccinated donors (n=6). The
286 serum was collected at early time point (7 days after second immunization). The
287 neutralization IC_{50} from individual donors is shown. Significance is based on the two-sided
288 t-test.
289
290 **Supplemental Figure S3.**
291 **Neutralization titers of spike protein pseudotyped viruses (single point mutations)**
292 **by monoclonal antibodies.**
293 Neutralization of variant spike protein variants (single point mutations) by REGN10933
294 and REGN10987 monoclonal antibodies. The IC_{50} of REGN10933, REGN10987 and the
295 cocktail is shown in the table.
296
297 **Acknowledgements**
298 The work was funded in part by grants from the NIH to N.R.L. (DA046100, AI122390 and
299 AI120898) and to M.J.M. (UM1AI148574). T.T. was supported by the Vilcek/Goldfarb
300 Fellowship Endowment Fund. M.J.M. and M.I.S. were partially supported by NYU
301 Grossman SOM institutional support.
302
303 **Author contributions**
304 T.T. and N.R.L. designed the experiments. H.Z., T.T. and B.M.D. carried out the
305 experiments and analyzed data. T.T., H.Z. and N.R.L. wrote the manuscript. M.I.S. and
306 M.J.M. designed and supervised the specimen selection, clinical information collection

307 and the N ELISAs, and provided key reagents and useful insights. All authors provided
308 critical comments on manuscript.
309
310 **Declaration of Interests**.
311 The authors declare no competing interests.
312

313 **References**

314 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2
315 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020;383(27):2603-
316 2615. DOI: 10.1056/NEJMoa2034577.

317 2. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose
318 Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine
319 2021;384(23):2187-2201. DOI: 10.1056/NEJMoa2101544.

320 3. World Health Organization.2021 (https://www.who.int/en/activities/tracking-SARS-
321 CoV-2-variants/).

322 4. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants
323 escape neutralization by vaccine-induced humoral immunity. Cell 2021. DOI:
324 10.1016/j.cell.2021.03.013.

325 5. Tada T, Dcosta BM, Samanovic MI, et al. Convalescent-Phase Sera and Vaccine-
326 Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-
327 2 Variant Spikes. mBio 2021;12(3):e0069621. DOI: 10.1128/mBio.00696-21.

328 6. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants
329 B.1.351 and B.1.1.7. Nature 2021. DOI: 10.1038/s41586-021-03398-2.

330 7. Wu K, Werner AP, Koch M, et al. Serum Neutralizing Activity Elicited by mRNA-
331 1273 Vaccine. New England Journal of Medicine 2021;384(15):1468-1470. DOI:
332 10.1056/NEJMc2102179.

333 8. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion,
334 E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine
335 2021;27(4):620-621. DOI: 10.1038/s41591-021-01270-4.

336 9. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other
337 SARS-CoV-2 variants. Nature 2021. DOI: 10.1038/s41586-021-03693-y.
338 10. Choi A, Koch M, Wu K, et al. Serum Neutralizing Activity of mRNA-1273 against
339 SARS-CoV-2 Variants. bioRxiv 2021:2021.06.28.449914. DOI:
340 10.1101/2021.06.28.449914.
341 11. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of infectious SARS-CoV-
342 2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and
343 vaccinated individuals. bioRxiv 2021:2021.05.26.445838. DOI:
344 10.1101/2021.05.26.445838.
345 12. Tada T, Dcosta BM, Zhou H, Vaill A, Kazmierski W, Landau NR. Decreased
346 neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein
347 monoclonal antibodies. bioRxiv 2021:2021.02.18.431897. DOI:
348 10.1101/2021.02.18.431897.
349 13. Tada T, Dcosta BM, Samanovic-Golden M, et al. Neutralization of viruses with
350 European, South African, and United States SARS-CoV-2 variant spike proteins
351 by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv
352 2021:2021.02.05.430003. DOI: 10.1101/2021.02.05.430003.
353 14. Tada T, Fan C, Chen JS, et al. An ACE2 Microbody Containing a Single
354 Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. Cell Rep
355 2020;33(12):108528. DOI: 10.1016/j.celrep.2020.108528.
356 15. Benton DJ, Wrobel AG, Roustan C, et al. The effect of the D614G substitution on
357 the structure of the spike glycoprotein of SARS-CoV-2. Proc Natl Acad Sci U S A
358 2021;118(9). DOI: 10.1073/pnas.2022586118.

359 16. Noval MG, Kaczmarek ME, Koide A, et al. Antibody isotype diversity against
360 SARS-CoV-2 is associated with differential serum neutralization capacities.
361 Scientific Reports 2021;11(1):5538. DOI: 10.1038/s41598-021-84913-3.
362 17. Gu H, Chen Q, Yang G, et al. Adaptation of SARS-CoV-2 in BALB/c mice for
363 testing vaccine efficacy. Science 2020;369(6511):1603-1607. DOI:
364 10.1126/science.abc4730.
365 18. Starr TN, Greaney AJ, Hilton SK, et al. Deep Mutational Scanning of SARS-CoV-
366 2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.
367 Cell 2020;182(5):1295-1310 e20. DOI: 10.1016/j.cell.2020.08.012.
368 19. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
369 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature
370 Medicine 2021;27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8.
371 20. Jongeneelen M, Kaszas K, Veldman D, et al. Ad26.COV2.S elicited neutralizing
372 activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv
373 2021:2021.07.01.450707. DOI: 10.1101/2021.07.01.450707.
374 21. Alter G, Yu J, Liu J, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-
375 CoV-2 variants in humans. Nature 2021. DOI: 10.1038/s41586-021-03681-2.
376 22. Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination
377 with ChAdOx1 nCoV-19 and BNT162b2 mRNA. medRxiv
378 2021:2021.07.03.21258887. DOI: 10.1101/2021.07.03.21258887.
379 23. Gross R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and
380 BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses

381 and T cell reactivity. medRxiv 2021:2021.05.30.21257971. DOI:
382 10.1101/2021.05.30.21257971.
383 24. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses
384 against SARS-CoV-2 variants after heterologous and homologous ChAdOx1
385 nCoV-19/BNT162b2 vaccination. Nature Medicine 2021. DOI: 10.1038/s41591-
386 021-01449-9.
387

388 **Table S1**. Neutralization of variants by convalescent sera, BNT162b2 and mRNA-1273 elicited antibodies

389 7 days post-second vaccination.

390

	Convalescent					
	IC_{50}(serum dilution)					
donor	D614G (B.1)	Alpha (B.1.1.7)	Beta (B.1.351)	Delta (B.1.617.2)	Delta plus (AY.1)	Lambda (C.37)
1	251	312	69	56	112	94
2	176	223	91	84	121	124
3	77	140	68	185	132	29
4	406	375	38	51	68	121
5	602	146	57	3	77	27
6	383	416	119	34	142	199
7	520	556	100	119	89	187
8	359	273	25	94	100	61
Mean (SD)	346 (174)	305 (142)	71 (32)	78 (56)	105 (26)	105 (66)

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

		BNT162b2					
		IC_{50}(serum dilution)					
donor	Days post last vaccine	D614G (B.1)	Alpha (B.1.1.7)	Beta (B.1.351)	Delta (B.1.617.2)	Delta plus (AY.1)	Lambda (C.37)
1	7	1915	1994	877	914	575	834
2	7	697	615	228	231	169	191
3	7	2572	2026	1366	950	1088	1244
4	7	939	925	145	507	171	123
5	7	1445	1717	161	416	361	167
6	7	2205	2069	413	370	614	935
7	7	1689	1259	918	560	1769	735
8	7	3189	2676	1045	1095	762	1032
9	7	1352	1720	456	594	363	451
10	7	1170	1355	604	669	796	635
11	7	672	729	219	398	592	238
12	7	571	841	364	441	480	259
13	7	3338	3099	1245	1463	1241	926
14	7	3486	3181	591	1042	685	1200
15	7	2294	2257	654	1092	1138	1888
Mean (SD)		1835 (986)	1764 (822)	619 (394)	716 (354)	720 (436)	724 (502)

		mRNA-1273					
		IC_{50}(serum dilution)					
donor	Days post last vaccine	D614G (B.1)	Alpha (B.1.1.7)	Beta (B.1.351)	Delta (B.1.617.2)	Delta plus (AY.1)	Lambda (C.37)
1	7	1380	1186	532	500	382	472
2	7	1963	1852	362	614	731	1185
3	7	1010	833	351	273	1055	209
4	7	1305	779	298	419	234	427
5	7	1879	2395	535	638	411	880
6	7	2028	1990	322	568	615	946
Mean (SD)		1594 (419)	1506 (668)	400 (106)	502 (138)	571 (296)	687 (373)

419 **Table S2.** Neutralization of viruses by sera from BNT162b2, mRNA-1273 and Ad26.COV.S vaccinated

420 individuals.

BNT162b2											
						IC_{50}(serum dilution)					
donor	Days post last vaccine	Anti-N ELISA	Age	Sex	Comorbidities	D614G	Alpha	Beta	Delta	Delta plus	Lambda
1	84	-	39	F	None	575	427	51	141	215	167
2	52	-	23	F	None	1338	1055	82	314	296	101
3	101	-	26	F	Asthma	1101	829	258	362	598	209
4	109	-	33	F	None	562	750	138	243	186	111
5	60	-	35	F	Hypothyroidism, Psoriasis	1024	930	53	239	391	284
6	81	-	42	F	Asthma	258	279	32	103	248	39
7	108	-	26	F	None	580	485	247	95	133	396
8	107	-	24	M	None	372	520	104	77	147	78
9	110	-	35	M	None	445	362	60	148	67	95
Mean (SD)	90 (22)		31			695 (369)	626 (272)	114 (85)	191 (102)	253 (161)	164 (114)

421
422

mRNA-1273											
						IC_{50}(serum dilution)					
donor	Days post last vaccine	Anti-N ELISA	Age	Sex	Comorbidities	D614G	Alpha	Beta	Delta	Delta plus	Lambda
1	89	-	26	M	None	984	1043	108	173	364	257
2	92	-	53	M	None	972	703	237	207	239	273
3	61	-	67	M	Prediabetes	774	544	87	68	264	139
4	93	-	33	F	None	509	443	58	209	82	91
5	44	-	32	M	None	856	579	273	203	365	258
6	100	-	29	F	None	1038	1014	305	295	312	274
7	52	-	33	F	None	990	968	145	322	213	152
8	105	-	55	F	Asthma	537	485	246	184	160	391
Mean (SD)	80 (24)		41			833 (209)	722 (249)	182 (94)	208 (77)	250 (99)	229 (96)

423

Ad26.COV2.S											
						IC_{50}(serum dilution)					
donor	Days post last vaccine	Anti-N ELISA	Age	Sex	Comorbidities	D614G	Alpha	Beta	Delta	Delta plus	Lambda
1	57	-	42	F	None	46	55	22	31	41	21
2	58	-	28	F	None	133	101	5	28	46	47
3	66	-	36	F	None	500	130	ND	ND	ND	ND
4	92	-	33	F	None	333	257	23	31	8	24
5	87	-	39	F	Prediabetes	244	205	19	42	31	36
6	72	-	32	M	None	268	308	79	34	63	59
7	92	-	39	F	None	251	377	44	46	38	70
8	71	-	75	F	None	298	648	ND	7	ND	ND
9	105	-	30	M	None	38	45	18	37	31	13
10	115	-	33	F	None	98	194	50	15	68	20
Mean (SD)	82 (20)		39			221 (144)	232 (182)	33 (24)	30 (12)	41 (19)	36 (21)


A
Convalescent
BNT162b2
mRNA-1273
IC50 (serum dilution)
x4.9
x4.4
x3.3
x3.2
x2.9
x2.5
x2.6
x3.2
x4.0
x3.2
x3.0
x2.6
D614G (B.1)
Alpha (B.1.1.7)
Beta (B.1.351)
Delta (B.1.617.2)
Delta plus (AY.1)
Lambda (C.37)
B
Convalescent
BNT162b2
mRNA-1273
Ad26.COV2.S
346 305 71 78 105 105
(x4.9) (x4.4) (x3.3) (x3.2)
695 626 114 191 253 164
(x6.1) (x3.6) (x2.7) (x4.2)
833 722 182 207 250 229
(x4.6) (x4.0) (x3.3) (x3.6)
221 232 33 30 41 36
(x6.7) (x7.4) (x5.4) (x6.1)
C
D614G (B.1)
Alpha (B.1.1.7)
Beta (B.1.351)
Delta (B.1.617.2)
Delta plus (AY.1)
Lambda (C.37)
P=0.0015
P<0.0001
P=0.0016
P=0.0002
P=0.0059
P=0.0001
P=0.0001
P<0.0001
P=0.0005
P<0.0001
P=0.0019
P<0.0001
BNT162b2
mRNA-1273
Ad26.COV2.S

Figure 1



	IC50 (ng/ml)				
	D614G (B.1)	Beta (B.1.351)	Delta (B.1.617.2)	Delta plus (AY.1)	Lambda (C.37)
REGN10933	3.3	420.4	39.1	306.3	2.9
REGN10987	9.3	16.4	28.8	29.7	33.7
REGN-COV2	4.4	33.1	9.8	19.5	7.0

Figure 2

A



B



Supplemental Figure S1



Supplemental Figure S2

A



	IC50 (ng/ml)									
	D614G	G75V-T76I	Δ246-252	L452Q	F490S	T859N	E484K	L452R	K417N	T478K
REGN10933	3.3	5.8	3.5	19.3	1.9	4.3	157.6	32.7	373.3	9.5
REGN10987	9.3	10.7	9.7	40.5	11.2	11.5	11.7	63.3	3.3	13.0
REGN-COV2	4.4	5.6	4.5	9.9	0.2	5.5	13.9	69.0	29.3	11.4

Supplemental Figure 3